BACKGROUND: Dengue virus (DENV) infection remains a major public health burden worldwide. Soluble mediators may play a critical role in the pathogenesis of acute DENV infection. Galectin-9 (Gal-9) is a soluble β-galactoside-binding lectin, with multiple immunoregulatory and inflammatory properties. OBJECTIVE: To investigate plasma Gal-9 levels as a biomarker for DENV infection. STUDY DESIGN: We enrolled 65 DENV infected patients during the 2010 epidemic in the Philippines and measured their plasma Gal-9 and cytokine/chemokine levels, DENV genotypes, and copy number during the critical and recovery phases of illness. RESULTS: During the critical phase, Gal-9 levels were significantly higher in DENV infected patients compared to healthy or those with non-dengue febrile illness. The highest Gal-9 levels were observed in dengue hemorrhagic fever (DHF) patients (DHF: 2464 pg/ml; dengue fever patients (DF): 1407 pg/ml; non-dengue febrile illness: 616 pg/ml; healthy: 196 pg/ml). In the recovery phase, Gal-9 levels significantly declined from peak levels in DF and DHF patients. Gal-9 levels tracked viral load, and were associated with multiple cytokines and chemokines (IL-1α, IL-8, IP-10, and VEGF), including monocyte frequencies and hematologic variables of coagulation. Further discriminant analyses showed that eotaxin, Gal-9, IFN-α2, and MCP-1 could detect 92% of DHF and 79.3% of DF, specifically (P<0.01). CONCLUSION: Gal-9 appears to track DENV inflammatory responses, and therefore, it could serve as an important novel biomarker of acute DENV infection and disease severity.
BACKGROUND:Dengue virus (DENV) infection remains a major public health burden worldwide. Soluble mediators may play a critical role in the pathogenesis of acute DENV infection. Galectin-9 (Gal-9) is a soluble β-galactoside-binding lectin, with multiple immunoregulatory and inflammatory properties. OBJECTIVE: To investigate plasma Gal-9 levels as a biomarker for DENVinfection. STUDY DESIGN: We enrolled 65 DENVinfectedpatients during the 2010 epidemic in the Philippines and measured their plasma Gal-9 and cytokine/chemokine levels, DENV genotypes, and copy number during the critical and recovery phases of illness. RESULTS: During the critical phase, Gal-9 levels were significantly higher in DENVinfectedpatients compared to healthy or those with non-dengue febrile illness. The highest Gal-9 levels were observed in dengue hemorrhagic fever (DHF) patients (DHF: 2464 pg/ml; dengue feverpatients (DF): 1407 pg/ml; non-dengue febrile illness: 616 pg/ml; healthy: 196 pg/ml). In the recovery phase, Gal-9 levels significantly declined from peak levels in DF and DHF patients. Gal-9 levels tracked viral load, and were associated with multiple cytokines and chemokines (IL-1α, IL-8, IP-10, and VEGF), including monocyte frequencies and hematologic variables of coagulation. Further discriminant analyses showed that eotaxin, Gal-9, IFN-α2, and MCP-1 could detect 92% of DHF and 79.3% of DF, specifically (P<0.01). CONCLUSION:Gal-9 appears to track DENV inflammatory responses, and therefore, it could serve as an important novel biomarker of acute DENV infection and disease severity.
Authors: D W Vaughn; A Nisalak; T Solomon; S Kalayanarooj; M D Nguyen; R Kneen; A Cuzzubbo; P L Devine Journal: Am J Trop Med Hyg Date: 1999-04 Impact factor: 2.345
Authors: Andrea R Stacey; Philip J Norris; Li Qin; Elizabeth A Haygreen; Elizabeth Taylor; John Heitman; Mila Lebedeva; Allan DeCamp; Dongfeng Li; Douglas Grove; Steven G Self; Persephone Borrow Journal: J Virol Date: 2009-01-28 Impact factor: 5.103
Authors: R Matsumoto; H Matsumoto; M Seki; M Hata; Y Asano; S Kanegasaki; R L Stevens; M Hirashima Journal: J Biol Chem Date: 1998-07-03 Impact factor: 5.157
Authors: Gerardo R Vasta; Hafiz Ahmed; Mihai Nita-Lazar; Aditi Banerjee; Marta Pasek; Surekha Shridhar; Prasun Guha; José A Fernández-Robledo Journal: Front Immunol Date: 2012-07-13 Impact factor: 7.561
Authors: Samir Bhatt; Peter W Gething; Oliver J Brady; Jane P Messina; Andrew W Farlow; Catherine L Moyes; John M Drake; John S Brownstein; Anne G Hoen; Osman Sankoh; Monica F Myers; Dylan B George; Thomas Jaenisch; G R William Wint; Cameron P Simmons; Thomas W Scott; Jeremy J Farrar; Simon I Hay Journal: Nature Date: 2013-04-07 Impact factor: 49.962
Authors: Katrin Schaefer; Nicholas E Webb; Mabel Pang; Jenny E Hernandez-Davies; Katharine P Lee; Pascual Gonzalez; Martin V Douglass; Benhur Lee; Linda G Baum Journal: Glycobiology Date: 2017-09-01 Impact factor: 4.313
Authors: Brian P McSharry; Simone K Forbes; John Z Cao; Selmir Avdic; Emily A Machala; David J Gottlieb; Allison Abendroth; Barry Slobedman Journal: J Virol Date: 2014-07-09 Impact factor: 5.103